Velocity-selective arterial spin labeling perfusion in the evaluation of treated high grade gliomas at 1.5 Tesla
Sebastian Lambrecht1,2, Dapeng Liu1,3, Omar Dzaye4, Matthias Holdhoff4, Peter van Zijl1,3, Qin Qin1,3, and Doris Lin1,3
1Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States, 2Institute of Neuroradiology, University Hospital LMU Munich, Munich, Germany, 3F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, United States, 4Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
Perfusion measures were compared between VSASL and DSC methods at 1.5T in 28 patients with treated high-grade glioma assigned into 2 groups: “tumor” (with detectable enhancing tumor, n=9) and “non-tumor” (without detectable tumor, n=19). All measures (rCBF and tSNR from VSASL, rCBV and rCBF from DSC) showed significant difference between “tumor” and “non-tumor” groups allowing reliable discrimination. In general, there was moderate to excellent agreement and correlation between these measures derived from VSASL vs. DSC. Hence, VSASL has potential to serve as a viable non-invasive alternative to DSC perfusion in the clinical disease surveillance without the need for exogenous contrast.
This abstract and the presentation materials are available to members only;
a login is required.